Allison Hoffman Sells 3,995 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 3,995 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $65,358.20. Following the completion of the sale, the general counsel directly owned 169,661 shares of the company’s stock, valued at approximately $2,775,653.96. This represents a 2.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Phreesia Stock Performance

PHR traded down $0.63 on Tuesday, reaching $15.76. 888,246 shares of the stock were exchanged, compared to its average volume of 1,011,187. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.44 and a quick ratio of 2.44. The company’s 50-day moving average price is $18.24 and its 200 day moving average price is $23.18. The firm has a market capitalization of $950.23 million, a PE ratio of -157.59 and a beta of 0.61. Phreesia, Inc. has a fifty-two week low of $15.41 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company had revenue of $120.33 million during the quarter, compared to the consensus estimate of $119.98 million. During the same period in the previous year, the company posted ($0.25) earnings per share. Phreesia’s revenue for the quarter was up 12.7% on a year-over-year basis. As a group, sell-side analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on PHR. Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a report on Friday, October 31st. Royal Bank Of Canada started coverage on shares of Phreesia in a research note on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $35.00 price target on shares of Phreesia in a research report on Monday, December 8th. Truist Financial set a $24.00 price objective on Phreesia in a report on Thursday, January 8th. Finally, Canaccord Genuity Group decreased their target price on Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.06.

Hedge Funds Weigh In On Phreesia

Institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Phreesia by 208.8% in the 1st quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after acquiring an additional 16,309 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Phreesia by 471.2% during the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after buying an additional 132,015 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Phreesia by 3.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after buying an additional 2,158 shares during the last quarter. NewEdge Advisors LLC increased its position in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after acquiring an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Phreesia by 0.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after acquiring an additional 2,402 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.